Blog
RSS FeedPosted by Michael Wonder on 24 Nov 2022
Outcome in relation to discussion of COVID-19 oral treatments – November 2022 PBAC meeting
24 November 2022 - A PBAC outcome in relation to discussion of COVID-19 oral treatments at the November 2022 meeting has ...
Posted by Michael Wonder on 03 Nov 2022
Outcome statement - September 2022 DUSC meeting
3 November 2022 - The outcome statement from the September 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 14 Oct 2022
Outcomes from the September 2022 PBAC intracycle meeting
14 October 2022 - The recommendations made by the PBAC in September 2022 relating to the listing of medicines on ...
Posted by Michael Wonder on 19 Aug 2022
Recommendations made by the PBAC - July 2022
19 August 2022 - The recommendations from the July 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 10 Jul 2022
PBAC recommendation for amendments to COVID-19 oral treatment restrictions
10 July 2022 - The PBAC recommended changes to the PBS eligibility criteria for both molnupiravir (Lagevrio) and nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 17 Jun 2022
Outcomes of the May 2022 PBAC intracycle meeting
17 June 2022 - The outcomes from the May 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 05 May 2022
Insights from the March 2022 PBAC meeting (part 4)
5 May 2022 - The apparent high recommendation rate for the March 2022 meeting does have some downsides. ...
Posted by Michael Wonder on 28 Apr 2022
Insights from the March 2022 PBAC meeting (part 3)
29 April 2022 - Wegovy was the first discrete medicine to have a stakeholder meeting before its consideration by the ...
Posted by Michael Wonder on 27 Apr 2022
Insights from the March 2022 PBAC meeting (part 2)
28 April 2022 The rejection of dostarlimab should not come as a surprise, the rejection of sotorsaib less so. ...
Posted by Michael Wonder on 26 Apr 2022
Insights from the March 2022 PBAC meeting (part 1)
26 April 2022 - Yesterday, we noted a recommendation rate of 78% which the highest value we have recorded since ...
Posted by Michael Wonder on 23 Apr 2022
Recommendations made by the PBAC - March 2022
22 April 2022 - The recommendations from the March 2022 PBAC meeting are now available. ...
Posted by Michael Wonder on 09 Apr 2022
PBAC recommendation for nirmatrelvir and ritonavir (Paxlovid) - March 2022
9 April 2022 - The PBAC undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 28 Feb 2022
New treatment for Australians with rare blood disease
28 February 2022 - Australians with paroxysmal nocturnal haemoglobinuria—a condition that produces defective blood cells—will have access to a new treatment ...
Posted by Michael Wonder on 25 Feb 2022
PBAC recommendation for molnupiravir (Lagevrio)
25 February 2022 - The PBAC undertook an expedited consideration of a sponsor submission (MSD) to add molnupiravir (Lagevrio) to the ...